[A new pharmacological treatment option for alcohol dependence discovered in transnational study: neurokinin-1 receptor antagonist as a possible therapy for alcoholism?].
Today solid evidence is available that pharmacological treatments can prevent relapse and improve clinically relevant outcomes in alcoholism. In a preclinical and experimental-clinical study George and colleagues first investigated the role of Substance P and its receptor (NK1R) in the context of alcoholism. They could demonstrate that either the blockade of the receptor, or the lack of the receptors leds to a decreased alcohol intake as well as reduced alcohol tolerance and craving concomitantly accompanied by improved general well-beeing.
Mutschler
Jochen
J
Klinik für Abhängiges Verhalten und Suchtmedizin, Zentralinstitut für Seelische Gesundheit, Mannheim. jochen.mutschler@zi-mannheim.de
Grosshans
Martin
M
Kiefer
Falk
F
D000328:Adult; D000427:Alcohol Deterrents / Q000009:adverse effects / Q000627:therapeutic use*; D000437:Alcoholism / Q000534:rehabilitation*; D000818:Animals; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D018345:Mice, Knockout; D008875:Middle Aged; D064729:Neurokinin-1 Receptor Antagonists; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018040:Receptors, Neurokinin-1 / Q000235:genetics; D012008:Recurrence; D012106:Research; D013373:Substance P / Q000502:physiology; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D055815:Young Adult
D000427:Alcohol Deterrents; C527551:LY686017; D064729:Neurokinin-1 Receptor Antagonists; D011725:Pyridines; D018040:Receptors, Neurokinin-1; D014230:Triazoles; D013373:Substance P